TY - JOUR
T1 - Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: Evidence to date
AU - Cinti, Francesca
AU - Moffa, Simona
AU - Impronta, Flavia
AU - Cefalo, Chiara Maria Assunta
AU - Sun, Vinsin Alice
AU - Sorice, Gianpio
AU - Mezza, Teresa
AU - Giaccari, Andrea
PY - 2017
Y1 - 2017
N2 - Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The promising results obtained in clinical trials show that SGLT2 significantly improves glycemic control and provides greater cardiovascular protection, combined with a reduction in body weight and blood pressure (BP). This review focuses on ertugliflozin, a new, highly selective, and reversible SGLT2 inhibitor. Clinical trials published to date show that ertugliflozin, both as a monotherapy and as an add-on to oral antidiabetic agents, is safe and effective in reducing glycosylated hemoglobin (HbA1c), body weight, and BP in T2DM patients.
AB - Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The promising results obtained in clinical trials show that SGLT2 significantly improves glycemic control and provides greater cardiovascular protection, combined with a reduction in body weight and blood pressure (BP). This review focuses on ertugliflozin, a new, highly selective, and reversible SGLT2 inhibitor. Clinical trials published to date show that ertugliflozin, both as a monotherapy and as an add-on to oral antidiabetic agents, is safe and effective in reducing glycosylated hemoglobin (HbA1c), body weight, and BP in T2DM patients.
KW - 3003
KW - Antidiabetic drugs
KW - Drug Discovery3003 Pharmaceutical Science
KW - Glycemic control
KW - Glycosylated hemoglobin
KW - Pharmacology
KW - Precision medicine
KW - Sodium-glucose cotransporter 2 inhibitors
KW - Type 1 diabetes mellitus
KW - Type 2 diabetes melÂlitus
KW - Weight reduction
KW - 3003
KW - Antidiabetic drugs
KW - Drug Discovery3003 Pharmaceutical Science
KW - Glycemic control
KW - Glycosylated hemoglobin
KW - Pharmacology
KW - Precision medicine
KW - Sodium-glucose cotransporter 2 inhibitors
KW - Type 1 diabetes mellitus
KW - Type 2 diabetes melÂlitus
KW - Weight reduction
UR - http://hdl.handle.net/10807/111697
UR - https://www.dovepress.com/getfile.php?fileid=38703
U2 - 10.2147/DDDT.S114932
DO - 10.2147/DDDT.S114932
M3 - Article
SN - 1177-8881
VL - 11
SP - 2905
EP - 2919
JO - Drug Design, Development and Therapy
JF - Drug Design, Development and Therapy
ER -
